 LEIDEN, Netherlands CAMBRIDGE, Mass., Sept. 06, 2021 GLOBE NEWSWIRE -- ProQR Therapeutics N.V. Nasdaq:PRQR, a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced a virtual oral presentation of data from the Companys Phase 12 Stellar trial of QR-421a at the EURETINA virtual congress held September 9-12, 2021. It is the first time the Stellar trial data is presented at a medical congress. The paper will be made available on the EURETINA platform at the start of the congress. 